Peer-Reviewed · Institutional · Government-Approved

The Clinical Research Behind Acidophilus Strain 2585

Four decades of microbiological research, institutional clinical records, an indexed publication, patents and veterinary field data converge on one organism. This hub walks through each evidence stream in turn — tagged by type, with its limitations stated — so you can weigh it on its own merits.

Indexed publication (PMID 10961107)

Institutional clinical records, 1994–2025

Granted patents (KZ 2004, Eurasian 2010)

40+

Years of development and use

Researchers & Institutions

Who Did The Work, And Where

Named researchers and named institutions are what make a historical record checkable. These are the people and bodies whose signatures appear on the primary documents.

Grigory Ivanovich Miroshnikov

The figure most consistently documented across the primary sources. Patent holder on both the 2004 Kazakhstan patent and the 2010 Eurasian patent, named on the production acts, and party to the 2019 commercial partnership with EnergyMax that led to current-scale production.

G. A. Gulyaeva and T. A. Kharitonova

Authors of the two clinical-use instructions developed at the Alma-Ata State Medical Institute (AGMI) in 1993–1994 and approved by the Pharmacological Commission of the Ministry of Health. Their dosing protocols were reaffirmed in the 2013 ANGEK professional statement.

Galina Maksimovna Ivanova

Co-author and signatory on multiple primary documents, including the 1985 production act and the KazNMU-adjacent research, carrying forward a line of inquiry into beneficial lactic-acid organisms described as beginning with Ivan Maximovich Ivanov.

Pichkhadze, Rusanov and Novoselov

Authors of the one independently indexed, peer-reviewed publication on the strain, conducted at the Kazakh National Medical University named after S. D. Asfendiyarov and published in Stomatologiia (Moskva) in 2000.

Kazakh National Medical University (KazNMU)

Almaty. Site of both the indexed 2000 publication and the published microbiological survey of dysbacteriosis patients, including the treated chronic-gastritis cohort described below.

1st Polyclinic Association / Central Clinical Hospital

Almaty. One of three institutions that recorded a physician-signed clinical act under the Ministry-approved protocol in 1994, alongside the Republican Polyclinic of the Military Medical Service and the Institute of Pediatrics.

Tier 1 — Published, Peer-Reviewed Research

Independently Searchable. Independently Indexed.

Pichkhadze G.M., Rusanov V.P., Novoselov V.E. — Stomatologiia (Moskva). 2000;79(4):22–27. PMID 10961107. Verifiable by any physician outside anything supplied by the company or by Kazakh institutional archives.

The study examined strain 2585 lactic-acid bacteria against four clinically significant organisms isolated from patients with open mandibular fractures under active wound infection: Candida albicans, Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli.

Rank	Organism	Clinical relevance
1 (strongest)	Candida albicans	Fungal wound colonisation — notably difficult to manage clinically
2	Pseudomonas aeruginosa	Common, often multidrug-resistant wound and hospital pathogen
3	Staphylococcus aureus	Leading wound-infection pathogen
4 (weakest of the four)	Escherichia coli	Common wound and systemic pathogen

What this establishes: under the conditions studied, strain 2585 showed measurable antagonistic activity against all four organisms tested. The abstract further reports that antibiotic-resistant clinical isolates of these organisms showed reduced epidemiological significance and demonstrated sensitivity to the antibiotics tested within approximately 3–4 days of exposure to the lactic-acid bacteria — strongest against P. aeruginosa, less so against S. aureus and E. coli.

What it does not establish: that Maxilin treats wound infections, fungal infections or antibiotic-resistant infections in practice; that it can replace antibiotic therapy; or that findings from wound isolates generalise to gut microbiome use of a modern sachet formulation. The resensitisation finding is an in vitro laboratory observation on bacterial isolates, not a clinical outcome in treated patients.

Look up PMID 10961107 on PubMed

Tier 2 — Human Clinical / Institutional

KazNMU: Dysbacteriosis and Gut Flora Correction

"Use of the domestic eubiotic 'Maksilin' for correction of the microflora of the gastrointestinal tract" — Kazakh National Medical University, Almaty. A microbiological survey of 80 adults with clinically diagnosed dysbacteriosis, with a treated 30-person chronic-gastritis subgroup.

Adults surveyed with dysbacteriosis

Chronic gastritis patients treated

4 wks

100 ml, 3× daily, before meals

25 / 30

No longer showed pronounced dysbacteriosis

Microbiological finding	At baseline (all 30)	After four weeks
Lactic-acid bacteria	None detected	✓ Lactobacilli reappeared
Cellulolytic bacteria	None detected	✓ Bifidobacteria reappeared
Lactose-negative E. coli	Present	✓ Reduced lactose-negative coliform counts
Staphylococci	Present	Not separately re-assessed in the excerpt
Proteus	Present	Not separately re-assessed in the excerpt
Yeast-like Candida	Present	Not separately re-assessed in the excerpt
Stool character	Loose, foul-smelling	✓ Normalised
Dyspeptic symptoms	Present	✓ Resolved

Limitations: this is institutional clinical research and is not described in the source as randomised or placebo-controlled. The source text does not state the size of the age-matched healthy comparison group, whether the 30-patient group was randomly selected, or whether outcome assessment was blinded. The full paper has not been independently reviewed beyond the excerpt provided (pp. 217–218). Five of the thirty patients retained mild residual findings.

Tier 2 — Physician-Signed Institutional Acts

Three Institutions, Three Populations, One Directional Finding

Between 1994 and 1995, three separate Almaty institutions treated three different populations under the same Ministry-approved protocol and recorded the same direction of change: reduction of lactose-negative coliforms and reappearance of bifidobacteria and acidophilic organisms.

Apr–Jun 1994 · act approved 29 July 1994

1st Polyclinic Association / Central Clinical Hospital, Almaty

General adult dysbacteriosis population, treated under the Ministry-approved protocol. Reported improved general condition and normalised digestion; reduced lactose-negative coliform counts with reappearance of bifidobacteria and acidophilic organisms. The act specifies no patient count, dosing or duration.

Aug–Oct 1994 · act signed 31 October 1994

Republican Polyclinic, Military Medical Service, KNB Republic of Kazakhstan

Women with genital infection and dysbacteriosis, treated by intravaginal application under bacteriological monitoring per Pharmacological Commission protocol No. 2 of 19 February 1994. Resolution of discharge, itching and mucosal inflammation; cervical mucus neutrophil function normalised by day 5–7; vaginal smears showed absence of putrefactive and pyogenic flora with Döderlein bacilli present post-treatment. Signed by Dr N. Poszdeeva (OB/GYN) and V. Kushtalova, with the official polyclinic seal. No control group or patient count is given in the act.

Oct–Dec 1994 · act approved March 1995

Institute of Pediatrics, Almaty

Children with intestinal dysbacteriosis, chronic colitis and secondary malabsorption, treated under bacteriological stool monitoring. Reported improved general condition and normalised digestion; reduced lactose-negative coliform counts and reappearance of bifidobacteria and acidophilus rods. The act specifies no patient count, dosing or duration.

Tier 3 — Government & Professional

Ministry-Approved Clinical-Use Instructions

Two clinical-use instructions for Maxilin were formally approved by the Pharmacological Commission of the Ministry of Health of the Republic of Kazakhstan, developed at the Alma-Ata State Medical Institute. A government body reviewed and stamped a specific dosing protocol — this is regulatory-record evidence, not company literature.

Instruction	Approved	Dosing as recorded
Vaginitis / gynaecological use	19 February 1994	Intravaginal, 2–50 ml, or soaked tampons 2–3 hours per day; 5–10 day course. No stated contraindications.
Dysbacteriosis / gastrointestinal use, age-based	1993	Infants under 6 months 1–30 ml; 6–12 months 30–60 ml; 1–5 years 60–120 ml; over 5 years 120–200 ml; adults 200–400 ml, 1–2× daily, 10 days to 2+ months. No stated adverse effects at these doses.

Earlier still, on 19 February 1993 the Pharmacological Commission registered the preparation — a pure culture of acidophilic bacteria, strain 2585 — as a natural medicine under Protocol No. 12.

In 2013 the Association of Nutritionists, Gastroenterologists and Endoscopists of Kazakhstan (ANGEK), chaired by Prof. E. A. Izatullaev, issued a professional statement describing Maxilin (culture 2585-1666) as indicated for gut-flora disturbances in post-cholecystectomy states, chronic pancreatitis, IBS, biliary dysfunction and hepatic steatosis. It reaffirmed the age-based dosing of 60–250 ml, one to three times daily, and is the most recent formal professional endorsement in the document set.

Scope of these approvals: these are historical Kazakh regulatory and professional records relating to the liquid preparation. They are not, and should not be read as, modern regulatory clearance from the FDA, the EMA or the Health Products Regulatory Authority. In Ireland and the EU, Maxilin is sold as a food supplement.

Gynaecological Application

Vaginal Microflora and the Gut–Vaginal Axis

Döderlein bacilli — the lactobacilli that dominate a healthy vaginal microbiome — belong to the same genus as the organism in Maxilin. That is the biological reason the 1994 protocol existed, and the reason the gut and vaginal microbiomes are increasingly studied together.

Döderlein bacilli restoration

The 1994 Republican Polyclinic act records vaginal smears showing Döderlein bacilli present after treatment where putrefactive and pyogenic flora had been found before it.

Cervical mucus normalisation in 5–7 days

Neutrophil function in cervical mucus was recorded as normalised by day five to seven, alongside resolution of discharge, itching and mucosal inflammation.

An approved prophylaxis protocol

The vaginitis and genital-infection instruction approved on 19 February 1994 set out intravaginal application of 2–50 ml, or soaked tampons for two to three hours daily, over a five to ten day course, with no stated contraindications.

Why the gut matters to it

The same lactobacilli genus populates both niches, and the intestinal reservoir is one route by which the vaginal microbiome is replenished. Restoring intestinal flora is therefore studied as part of the same picture rather than a separate one.

Please read this carefully: the gynaecological record describes a 1994 institutional clinical act with no control group and no patient count, using the historical liquid preparation under an intravaginal protocol supervised by physicians. It is not a controlled trial, the dry sachet has not been tested this way, and nothing here should be taken as guidance to self-treat a genital infection. Persistent or recurrent symptoms need assessment by a doctor.

Tier 6 — Veterinary & Agricultural Field Evidence

Cross-Species Corroboration At Scale

Veterinary field data cannot substitute for human clinical evidence. What it does provide is biological corroboration across species, in population sizes no human study of this product has matched.

133,232

Piglets in the Volynsky field programme

1,277

Fewer losses to diarrhoea / dysbacteriosis

+0.4 kg

Reported weaning-weight gain per head

4–5%

Improved bird survivability

Swine — "Volynsky" agricultural complex, 1985–1989

Across 133,232 piglets, the historical field document reports approximately 1,277 fewer losses attributed to diarrhoea and dysbacteriosis after the strain-2585 preparation was introduced — roughly 1% of the total population — together with approximately 0.4 kg greater rearing weight per head.

The same complex used the preparation intrauterine across 500 sows to treat metritis, with acts reporting resolution of metritis signs by day three and oestrus resuming six to seven days after weaning. Those acts note it replaced antibiotic treatment, which had passed into piglets via milk and disrupted their resident flora. A 1982 toxicology screen found no pathogenicity in a mouse bioassay.

Poultry — Almaty Kus / Alel-Agro, 2006 onward

In two poultry houses affected by colibacillosis and coccidiosis, daily mortality of 300–350 birds fell to 40–100 birds after four days of Maxilin at 2 ml per kg of feed.

Scaled operation-wide at roughly 10 kg per tonne of feed for up to 40 days with no antibiotics required, the programme reported 4–5% improved bird survivability, 25–40% improved livestock survivability across applications, 1–1.5% improved egg-laying rate, stronger eggshells and a 2% economic gain above plan from October 2006. Kazakhstan's Nutrition Academy found treated-bird meat met high-quality, ecologically clean standards.

For veterinary and B2B enquiries: the field reports are signed by the board chairman, deputy chairman, chief accountant, chief technologist, chief veterinarian and the producer (TOO MAX-IGM), under the official corporate seal. Contact us for the livestock and poultry documentation.

Composition & Mechanism

B-Vitamins, Amino Acids and Short-Chain Organic Acids

A fermented acidophilus preparation is not only a delivery vehicle for bacteria. The fermentation itself produces metabolites, and the historical documentation attributes part of the observed effect to them.

Short-chain organic acids

Lactic-acid fermentation lowers local pH and produces short-chain organic acids. The historical documentation attributes the preparation's antagonism toward putrefactive and pyogenic flora in part to this acidified environment, which opportunistic organisms tolerate poorly.

B-complex vitamins and vitamin C

Lactobacilli synthesise B-group vitamins during fermentation, and the independent March 2025 Antigen analysis measured vitamin C at 67.6 mg per 100 ml by HPLC-DAD. The dry sachet includes vitamin C directly in its formulation.

Protein and essential amino acids

The same analysis measured protein at 5.6 g per 100 ml of the liquid by GOST 30648.2-99, with the dry material reported at 31.89% protein. Fermentation partially pre-digests milk protein, which is the basis of the historical claims about amino-acid availability.

Minerals

Potassium 362.8 mg and magnesium 194.2 mg per 100 ml, with zinc, iron and copper at 0.908, 0.129 and 0.024 mg respectively. The calcium figure in the source protocol is flagged for confirmation and is not used as a nutritional claim.

On immune effects: the proposition that restoring intestinal microbiota supports immune function is a general and well-supported principle of microbiome science. It is not a specific, trial-demonstrated finding for this product, and the documents in this set do not test it directly.

How To Weigh It

The Evidence Hierarchy

Each stream contributes something different, and each has a ceiling. Both are set out below exactly as the physician dossier states them.

Tier	What exists	What it contributes	What it cannot establish
1. Published research	1 indexed paper (PMID 10961107)	Independently verifiable, peer-reviewed antagonism data	Clinical efficacy; gut-microbiome relevance
2. Human clinical / institutional	KazNMU study; 3 institutional acts	Human outcome and microbiology data under real treatment	Randomised-trial-level proof; blinding
3. Government / professional	2 Ministry instructions; ANGEK 2013 statement	Regulatory-body-reviewed dosing and indication scope	Modern regulatory clearance (FDA / EMA)
4. Laboratory validation	2025 Antigen protocol; 2024 ATU report	Independent compositional and viable-count analysis	Efficacy; sachet-specific composition
5. Patents / IP	Kazakhstan 2004; Eurasian 2010	Novelty and intellectual-property protection	Clinical efficacy of any kind
6. Veterinary field	Swine and poultry programmes	Cross-species biological corroboration	Human clinical proof
7. Practitioner testimony	Physician accounts and one reported case	Clinical hypotheses; real-world signal	Controlled evidence of any kind
8. Marketplace observation	Distributor feedback on the powder form	Early commercial signal	Any form of clinical or compositional equivalence

What Remains To Be Studied

From Historical Evidence to Modern Microbiome Science

Stated once, plainly: contemporary randomised, placebo-controlled, blinded human trials conducted on the current sachet formulation do not exist. That is the central evidence gap. The historical record is unusual not because every question has been answered, but because multiple independent streams converge on the same organism and the same reported behaviour — which is what makes the remaining questions worth asking.

Independent analytical testing of the actual sachet — identity, purity and viable CFU at expiration.
A prospective, controlled human trial on the sachet formulation for a specific, well-defined indication.
Full-text verification of the Pichkhadze et al. (2000) antibiotic-susceptibility findings.
Strain genomic characterisation and modern taxonomic confirmation.
Modern gut-microbiome sequencing (16S or shotgun) before and after supplementation.
Viable-CFU testing through expiration and simulated GI transit, which would directly test the lyophilisation and microencapsulation steps.
Structured antibiotic-co-administration studies, given the documented tolerance profile.
A controlled dysbiosis study replicating and extending the KazNMU protocol.
Publication of a modern case series as a first step toward a registered trial.

Primary Sources

Read The Underlying Documents

Nothing on this page asks to be taken on trust. Both compilations are published in full, with the original Russian-language records reproduced alongside English translations.

Maxilin scientific and regulatory dossier for physicians, cover page

Scientific & Regulatory Dossier — Physician Edition

The full 21-page dossier, including the source document index, the evidence hierarchy and the consolidated limitations section.

Open the dossier (PDF)

KazNMU research paper on Maxilin eubiotic for correction of gastrointestinal microflora

KazNMU Dysbacteriosis Research Paper

The published microbiological survey from the Kazakh National Medical University, reproduced with its English translation in the source document compilation.

Open the source documents (PDF)

Summary of the indexed PubMed study PMID 10961107 on strain 2585 antagonistic activity

Indexed Publication — PMID 10961107

The reported hierarchy of antagonistic activity against C. albicans, P. aeruginosa, S. aureus and E. coli, with the scope of the finding set out explicitly.

View the record on PubMed

Veterinary & Field Evidence

The swine and poultry field programmes, including the signed Almaty Kus and Alel-Agro report and the 1982 toxicology clearance.

Read the veterinary section

A note on the translations: the compilation states that its documents are provided as a guide only and that official copies should be requested from the office. Contact us if you need certified copies for professional or regulatory purposes.